SOLNA, Sweden & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (OMX Nordic Exchange: AERO)(STO:AERO-B) today announces the signing of an exclusive agreement with Danish medical device company Intramedic AB for distribution of Aerocrine’s new airway inflammation monitor and test kit – NIOX VERO® – in Sweden.
The agreement goes into effect on January 1, 2014 and gives Intramedic exclusive rights for the sales and distribution of Aerocrine’s new instrument NIOX VERO® and test kits, used for diagnosing and monitoring patients with asthma. The agreement also includes Intramedic taking on the support, sales and distribution for the already installed base of Aerocrine’s NIOX MINO® devices in the Swedish market.
“As we prepare to launch our new product NIOX VERO® in Sweden, we are very pleased to partner with Intramedic, who is a leading sales and marketing distributor with an existing and substantial Swedish operation who has proven track record of success with NIOX products from the Danish market, a well-fitting product portfolio and a customer-oriented corporate culture. This deal is part of Aerocrine’s strategy of substantially growing the European business in a cost-efficient manner,” says Linus Norrbom, International Sales Director at Aerocrine AB.
Aerocrine is committed to maintaining a direct presence in the Swedish market to support development of FeNO guidelines, KOL management and engagement with payers. Aerocrine will continue to focus on developing opportunities in new healthcare environments such as pharmacy and occupational health.
Aerocrine offers versatile and easy-to-use monitoring devices for fractional exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for research and clinical applications are used for routine measurements in both specialist and primary care clinics, and can be used to improve the management of allergic airway inflammation, such as asthma.
Intramedic has been the exclusive distributor of Aerocrine’s products in Denmark for a number of years. The Danish partner successfully launched the NIOX MINO®, the predecessor to NIOX VERO®, in Denmark and built an impressive base of installed devices that generate significant sales of test kits.
“We are very proud to become Aerocrine’s exclusive distributor for Sweden and look forward to working with both existing and new customers in this market while also supporting Aerocrine’s efforts to further establish FeNO-testing as standard of care method for measuring allergic airway inflammation in the Swedish healthcare system,” says Jan Rando, CEO of Intramedic.
NIOX VERO® and NIOX MINO® offer added advantages for patient care, including detecting allergic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy.
Intramedic is a privately owned dynamic and expanding medical device company with subsidiaries in Denmark and Sweden. Intramedic is marketing and maintaining systems from a variety of the world’s leading manufacturers within cardiopulmonary diagnostics, biomechanics and rehabilitation.www.intramedic.dk (http://www.intramedic.dk/om-os/about-us/)
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on December 18, 2013.
This information was brought to you by Cision http://news.cision.com